New research suggests that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt traditional lifestyle programs.
Findings released in a leading medical journal demonstrates that while overweight people often shed substantial amounts of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Users using these drugs should be aware of the potential of fast rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.
That rate of recovery suggests a return to original weight within about 18 months.
Comparing Therapies
The research, which looked at 37 of trials involving thousands of patients, contrasted the outcomes of these new drugs with conventional dieting.
Scientists emphasize that individuals who shed pounds through diet and exercise typically have a less rapid creep back—approximately 100 grams monthly—once they finish.
Understanding the Fast Regain
Doctors propose the mode of action of the drugs accounts for the amplified weight return.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production may cause the system to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' means hunger is no longer kept in check, making excessive eating far more likely."
A Lifelong Issue?
Health authorities recommend the jabs for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, due to the significant potential of weight regain, the therapy is often life-long.
This opinion is echoed by pharmaceutical companies, who say that the findings "underscore the persistent nature of excess weight," comparing it to managing conditions like hypertension.
User Experiences
People who have come off the medication report a sudden return of hunger.
"It felt as if a trigger that goes on and I was suddenly extremely hungry," said one woman.
This difficulty is compounded if patients have not adopted permanent lifestyle or habit changes during therapy.
Growing Use
Recent estimates suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is higher among women compared to men.
- The middle-aged age group shows the greatest usage rates.
- Many access the medications through private healthcare rather than public health services.
Finally, experts stress that while GLP-1 drugs are effective tools for weight loss, they are not a magic fix and maintained weight loss relies on ongoing lifestyle management.
